in Wound Care
PATHELEN® Chronical Wound Treatment
A new therapy to treat wound infections also with MRSA, MDR, ESBL, and other antibiotic-resistant-bacteria (Superbugs)
PAWT is a unique therapy which cures the most common chronic wound diseases such as diabetic foot ulcer (DFS), pressure ulcer (Dekubitus), and venous ulcers (ulcus cruris).
Through its revolutionary strategy, a local physical adsorption treatment of wound bacteria is used instead of the traditional approach of a systemic antibiotic treatment. PAWT can even successfully treat “hard-to heal” wound infections, which are “protected” by a Biofilm or wounds which are contaminated with antibiotic resistant MRSA and Extended spectrum beta lactamases (ESBL) producing bacteria like Escherichia coli (EHEC; E.coli) and Klebsiella.
The unique effect of PATHELEN® THERAPY is achieved through various simultaneous complex mechanisms of:
- Prevention and elimination of the biofilm
- Sorption of pus and toxins (including large amounts of problematic lipopolysaccharides)
- Preparation of a physiological wound environment with granulating tissue
The first ambulant PAWT facility is planned to open in Switzerland in 2020.
It can be observed that the general condition of a patient improves significantly after the first application of Pathelen® along with a decrease in wound pain. Additionally, the application of the first PATHELEN® Treatment reduces the risk of a sepsis significantly.
Successful treatments of MRSA infected wounds
You don’t have an account yet? Request one directly: email@example.com
Case Studie: Z.V. male, 68 y.o.
- Type 2 diabetes mellitus
- diabetic foot syndrome neuroischemic form;
- wound infection of the left foot after amputation of fingers.
- Staphylococcus aureus
- Staphylococcus epidermidis
- Enterococcus faecium
Case relevant history
- Ischemic heart disease
- Hypertensive heart disease
- Heart failure
- Atrial fibrillation is a permanent form
|Date||Day of treatment||White blood cells||Banded neutrophils|
|2015-04-20||1 (before surgery)||14.0×109/L||19%|
|2015-04-20||1 (after surgery)||12.3×109/L||15%|
|2015-04-21||2 (start treatment by Pathelen)||11.9.x109/L||15%|